Among the numerous drugs containing UDCA and currently available on the domestic pharmaceutical market, the use of Choludexan, represented by the well-known company World Medicine, is of interest. Each capsule of Choludexan, produced from a high quality substance in accordance with international standards, contains 300 mg of UDCA. The inclusion of Choludexan in the treatment regimens for viral hepatitis is an option for additional pathogenetic therapy, which improves the well-being of patients, normalizes the activity of transaminases in the blood serum, does not require significant financial costs and can be carried out both in inpatient and outpatient settings.
Published in the journal «District Doctor» October-November’2017